Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating
patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes
(mutations) to genes that control the way cells function. Laboratory studies have shown that
olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and
ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.